BIOMAT Database Logo BIOMAT Database Logo

Long-acting muscarinic M3 receptor antagonists. 2006

Peter Norman
Norman Consulting, 18 Pink Lane, Burnham, Buckinghamshire, SL1 8JW, UK.

Two applications claim a novel class of muscarinic M(3) receptor antagonists and their use as long-acting agents for the treatment of chronic obstructive pulmonary disease. The two applications claim closely related structures with one claiming quaternary amine salts of the tertiary amines claimed in the other. The claimed compounds comprise a biarylmethylamine core with the amino group modified by acylation or sulfonation and a tertiary or quaternary amine coupled to the distal ring of the biaryl system.

UI MeSH Term Description Entries

Related Publications

Peter Norman
Long-acting muscarinic antagonists.
January 2015, Expert review of clinical pharmacology,
Peter Norman
Discovery of novel and long acting muscarinic acetylcholine receptor antagonists.
August 2008, Journal of medicinal chemistry,
Peter Norman
Long-acting muscarinic receptor antagonists for the treatment of respiratory disease.
June 2013, Pulmonary pharmacology & therapeutics,
Peter Norman
Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists.
November 2018, Proceedings of the National Academy of Sciences of the United States of America,
Peter Norman
Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases.
March 2014, Therapeutic advances in chronic disease,
Peter Norman
Novel long-acting antagonists of muscarinic ACh receptors.
May 2018, British journal of pharmacology,
Peter Norman
Pre-clinical and clinical pharmacology of selective muscarinic M3 receptor antagonists.
January 1995, Life sciences,
Peter Norman
Unbinding Kinetics of Muscarinic M3 Receptor Antagonists Explained by Metadynamics Simulations.
May 2023, Journal of chemical information and modeling,
Peter Norman
Discovery of biphenyl piperazines as novel and long acting muscarinic acetylcholine receptor antagonists.
October 2008, Journal of medicinal chemistry,
Peter Norman
Discovery of Novel Potent Muscarinic M3 Receptor Antagonists with Proper Plasma Stability by Structural Recombination of Marketed M3 Antagonists.
August 2017, ChemMedChem,
Copied contents to your clipboard!